Overview

A Study to Evaluate the Efficacy of Osimertinib in Patients With EGFR-sensitive Mutated Non-small Cell Lung Cancer Progression After Receiving Adjuvant Targeted Therapy Following Radical Surgery

Status:
NOT_YET_RECRUITING

Trial end date:
2028-05-01

Target enrollment:

Participant gender:

Summary

This study aims to verify the efficacy and safety of osimertinib in patients with EGFR-sensitive mutation non-small cell lung cancer who progressed after adjuvant targeted therapy following radical surgery. The main questions it aims to answer is: whether EGFR-TKI is effective in the re-treatment of NSCLC after postoperative adjuvant targeted therapy relapse.

Phase:

PHASE2

Details

Lead Sponsor:

Jin Ying

Treatments:

osimertinib